303 related articles for article (PubMed ID: 26961140)
1. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
Bulfoni M; Gerratana L; Del Ben F; Marzinotto S; Sorrentino M; Turetta M; Scoles G; Toffoletto B; Isola M; Beltrami CA; Di Loreto C; Beltrami AP; Puglisi F; Cesselli D
Breast Cancer Res; 2016 Mar; 18(1):30. PubMed ID: 26961140
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
3. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
4. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
[TBL] [Abstract][Full Text] [Related]
7. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
[TBL] [Abstract][Full Text] [Related]
9. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Manifestations of Epithelial-Mesenchymal Plasticity of Circulating Tumor Cells in Breast Cancer Patients.
Tashireva LA; Savelieva OE; Grigoryeva ES; Nikitin YV; Denisov EV; Vtorushin SV; Zavyalova MV; Cherdyntseva NV; Perelmuter VM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801519
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.
Fischer C; Turchinovich A; Feisst M; Riedel F; Haßdenteufel K; Scharli P; Hartkopf AD; Brucker SY; Michel L; Burwinkel B; Schneeweiss A; Wallwiener M; Deutsch TM
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076930
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
16. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
Ye Z; Wang C; Wan S; Mu Z; Zhang Z; Abu-Khalaf MM; Fellin FM; Silver DP; Neupane M; Jaslow RJ; Bhattacharya S; Tsangaris TN; Chervoneva I; Berger A; Austin L; Palazzo JP; Myers RE; Pancholy N; Toorkey D; Yao K; Krall M; Li X; Chen X; Fu X; Xing J; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
Eur J Cancer; 2019 Jan; 106():133-143. PubMed ID: 30528798
[TBL] [Abstract][Full Text] [Related]
17. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676
[TBL] [Abstract][Full Text] [Related]
18. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
19. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack.
Bulfoni M; Turetta M; Del Ben F; Di Loreto C; Beltrami AP; Cesselli D
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27783057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
